HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lavee, J. Articles by Mohr, R. Search for Related Content PubMed PubMed Citation Articles by Lavee, J. Articles by Mohr, R.

The Annals of Thoracic Surgery, Vol 53, 477-481, Copyright © 1992 by The Society of Thoracic Surgeons

ARTICLES

Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study

J Lavee, N Savion, A Smolinsky, DA Goor and R Mohr
Department of Cardiac Surgery, Chaim Sheba Medical Center, Tel Hashomer, Israel.

To evaluate the functional integrity of platelets in patients administered the proteinase inhibitor aprotinin during cardiopulmonary bypass, 20 patients undergoing a complicated and prolonged open heart operation were studied. They were randomized to receive either a high dose of aprotinin (total dose, 6 to 7 x 10(6) KIU) before and during cardiopulmonary bypass (10 patients) or a placebo (10 patients). Blood samples were collected preoperatively, at the termination of bypass, and 90 minutes thereafter to assess platelet count and aggregation on extracellular matrix, which was studied by scanning electron microscopy. On a scale of 1 to 4, mean preoperative platelet aggregation grades were similar in both groups (3.5 +/- 0.5). Postoperatively, at the termination of cardiopulmonary bypass and 90 minutes thereafter, all 10 patients treated with aprotinin revealed normal, unchanged platelet aggregation (grade, 3.5 +/- 0.5), whereas all placebo-treated patients showed severely disturbed aggregation (grade, 1.4 +/- 0.5) (p less than 0.001). The platelet count was similar in both groups before and after operation (preoperatively, 182 +/- 75 x 10(9)/L and 146 +/- 30 x 10(9)/L, and postoperatively, 87 +/- 13 x 10(9)/L and 80 +/- 27 x 10(9)/L for the aprotinin and placebo groups, respectively). Total 24-hour postoperative bleeding and blood requirement were significantly lower in the aprotinin group (371 +/- 84 mL and 2 +/- 0.7 units, respectively) compared with the placebo group (608 +/- 28 mL and 3.4 +/- 1.3 units, respectively) (p less than 0.01). These results demonstrate that improved postoperative hemostasis is directly related to the complete preservation of platelet function achieved by the protective properties of aprotinin.

This article has been cited by other articles:

				J. R. S. Day, R. C. Landis, and K. M. Taylor Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2006; 10(2): 132 - 142. [Abstract] [PDF]

				D. M. Arnold, D. A. Fergusson, A. K.C. Chan, R. J. Cook, G. A. Fraser, W. Lim, M. A. Blajchman, and D. J. Cook Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth. Analg., March 1, 2006; 102(3): 731 - 737. [Abstract] [Full Text] [PDF]

				P. J. Hess Jr. Systemic inflammatory response to coronary artery bypass graft surgery Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S6 - S9. [Abstract] [Full Text] [PDF]

				A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF]

				F. Forestier, S. Belisle, D. Robitaille, R. Martineau, L. P. Perrault, and J.-F. Hardy Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2000; 69(2): 452 - 456. [Abstract] [Full Text] [PDF]

				M. Klein, P.R. Keith, H.-P. Dauben, H.D. Schulte, H. Beckmann, G. Mayer, O. Elert, and E. Gams Aprotinin counterbalances an increased risk of peri-operative haemorrhage in CABG patients pre-treated with Aspirin Eur. J. Cardiothorac. Surg., October 1, 1999; 14(4): 360 - 366. [Abstract] [Full Text] [PDF]

				J. A. Hyde, J. A Chinn, and T. R Graham Platelets and cardiopulmonary bypass Perfusion, December 1, 1998; 13(6): 389 - 407. [PDF]

				J. L. Mac Hale, N. Nathan, and M. D'Ambra Intrinsic Anticoagulation: Protein C, Protein S, and Thrombomodulin Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 319 - 332. [Abstract] [PDF]

				M. N. D'Ambra, C. W. Akins, E. H. Blackstone, S. L. Bonney, L. H. Cohn, D. M. Cosgrove, J. H. Levy, K. E. Lynch, and R. Maddi APROTININ IN PRIMARY VALVE REPLACEMENT AND RECONSTRUCTION: A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1081 - 1089. [Abstract] [Full Text]

				C. Primack, J. M. Walenga, M. J. Koza, T. V. Shankey, and R. Pifarre Aprotinin Modulation of Platelet Activation in Patients Undergoing Cardiopulmonary Bypass Operations Ann. Thorac. Surg., April 1, 1996; 61(4): 1188 - 1193. [Abstract] [Full Text]

				Y. Moshkovitz, A. Lusky, and R. Mohr CORONARY ARTERY BYPASS WITHOUT CARDIOPULMONARY BYPASS: ANALYSIS OF SHORT-TERM AND MID-TERM OUTCOME IN 220 PATIENTS J. Thorac. Cardiovasc. Surg., October 1, 1995; 110(4): 979 - 987. [Abstract] [Full Text]

				H. P. Wendel, W. Heller, J. Michel, G. Mayer, C. Ochsenfahrt, U. Graeter, J. Schulze, H.-M. Hoffmeister, and H.-E. Hoffmeister Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage J. Thorac. Cardiovasc. Surg., June 1, 1995; 109(6): 1164 - 1172. [Abstract] [Full Text]

				A. Shinfeld, D. Zippel, J. Lavee, A. Lusky, E. Shinar, N. Savion, and R. Mohr Aprotinin Improves Hemostasis After Cardiopulmonary Bypass Better Than Single-Donor Platelet Concentrate Ann. Thorac. Surg., April 1, 1995; 59(4): 872 - 876. [Abstract] [Full Text]

				B. Blauhut, W. Harringer, P. Bettelheim, J. E. Doran, P. Spath, and P. Lundsgaard-Hansen Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1083 - 1091. [Abstract] [Full Text]

				P. O. Daily, J. A. Lamphere, W. P. Dembitsky, R. M. Adamson, and N. F. Dans Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass graftingA randomized, prospective, double-blind study J. Thorac. Cardiovasc. Surg., July 1, 1994; 108(1): 99 - 108. [Abstract] [Full Text]

				J. M. Murkin, J. Lux, N. A. Shannon, G. M. Guiraudon, A. H. Menkis, F. N. McKenzie, and R. J. Novick Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 554 - 561. [Abstract] [Full Text]